Nexium I.V. (Esomeprazole)

Esomeprazole works by binding irreversibly to the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the secretory surface of parietal cells. This inhibition blocks the final step of acid production, leading to a sustained rise in gastric pH and allowing damaged mucosa to heal.

The dose of Nexium I.V. is determined by the prescribing clinician based on the patient’s condition, severity, and clinical response. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed for individual patients.

Safety data for esomeprazole injection during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Nexium I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Nexium I.V. (esomeprazole) offers a more potent and consistent acid‑suppression profile compared with earlier‑generation PPIs such as omeprazole injection. Its stereoselective formulation provides higher bioavailability and a longer duration of action, which can be advantageous in acute care settings where rapid and sustained gastric pH control is needed.

Nexium I.V. must be stored at 2‑8 °C in a refrigerator, protected from light. The solution should not be frozen or shaken. Before administration, allow the product to reach room temperature if required by local practice, and inspect for any particulate matter or discoloration.

Nexium I.V. is given by intravenous infusion, typically diluted in a compatible carrier solution and administered over a short period as directed by the prescriber. The infusion rate and duration are adjusted according to the clinical indication and patient response, and the medication should be administered by qualified healthcare personnel.

Serious adverse reactions associated with Nexium I.V. include Clostridioides difficile‑associated colitis, severe hypomagnesemia, and anaphylactic or severe allergic reactions. Patients should be monitored for signs of infection, electrolyte disturbances, and any sudden skin or respiratory symptoms, and treatment should be stopped immediately if such events occur.

Nexium I.V. is contraindicated in patients with known hypersensitivity to esomeprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, as well as those who have experienced previous severe reactions to PPIs.